“The constipation from GLP-1s is permanent.”
What the evidence shows
Constipation is a well-documented GI side effect: in the pivotal semaglutide obesity trials it was reported by roughly 23% of participants, and it's listed on the FDA label. It stems largely from how the drug works — slowed stomach and gut transit — so it clusters during dose escalation and tends to ease as the body adjusts. It's generally manageable with the ordinary toolkit (fluids, fiber, activity, and, when a clinician advises, a laxative), responds to slowing or lowering the dose, and reverses when the medication is stopped.
What we still don’t know
We don't have precise figures on how long constipation lasts on average, who is most prone to it, or how much each self-care measure helps in this specific setting versus just time and dose adjustment. Individual experiences vary widely.
Why the claim misleads
"Permanent" turns a common, reversible, dose-related nuisance into a life sentence. For most people it's worst early and improves; when it doesn't, it's usually workable with a clinician's help through hydration, fiber, dose timing, or a stool softener — and it lifts once the drug is discontinued. Constipation that becomes severe, or comes with significant pain, vomiting, or no bowel movement for days, is a reason to check in with a clinician, not evidence of permanent damage.
Graded by The Peptide Era · evidence, not hype